＜2004＞
1. Toyokawa T, Yokota K, Mizuno M, Fujinami Y, Takenaka R, Okada H, Hayashi S, Hirai Y, Oguma K, and Shiratori S. Characterization of elongated Helicobacter pylori isolated from a patient with gastric-mucosa-associated lymphoid-tissue lymphoma. J. Med. Microbiol. 53: 1-6, 2004.
2. Yamasaki R, Yokota K, Okada H, Hayashi S, Mizuno M, Yoshino T, Hirai Y, Saitou D, Akagi T, and Oguma K. Immune response in Helicobacter pylori-induced low-grade gastric-mucosa-associated lymphoid tissue (MALT) lymphoma. J Med Microbiol. 53:21-29, 2004.
3. Fujinaga Y, Inoue K, Watarai S, Sakaguchi Y, Arimitsu H, Lee J, Jin Y, Matsumura T, Kabumoto Y, Watanabe T, Ohyama T, Nishikawa A, and Oguma K. Molecular characterization of binding subcomponents of Clostridium botulinum type C progenitor toxin for intestinal epithelial cells and erythrocytes. Microbiol. 150: 1529-1538, 2004.
4. Arimitsu H, Lee J, Sakaguchi Y, Hayakawa Y, Hayashi M, Nakaura M, Takai H, Lin SN, Mukamoto M, Murphy T, and Oguma K. Vaccination with recombinant whole heavy chain fragments of Clostridium botulinum type C and D neurotoxins. Clin Diagn Lab Immunol. 11: 496-502, 2004.
5. Nishikawa A, Uotsu N, Miura Y, Arimitsu H, Lee J, Fujinaga Y, Nakada H, Ohyama T, Sakano Y, and Oguma K. The receptor and transporter for internalization of Clostridium botulinum type C progenitor toxin into HT-29 cells. Biochem. Biophysic Res. Communi. 319: 327-333, 2004.
6. Ishiki K, Mizuno M, Take S, Nagahara Y, Yoshida T, Yamamoto K, Okada H, Yokota K, Oguma K, and Shiratori Y. Helicobacter pylori eradication improves pre-existing reflux esophagitis in patients with duodenal disease. Clin. Gastroenterol. Hepatol. 2: 474-479, 2004.
7. Takenaka R, Yokota K, Mizuno M, Okada H, Toyokawa T, Yamasaki R, Yoshino T, Sugiyama T, Asaka M, Shiratori Y, and Oguma K. Serum antibodies to Helicobacter pylori and its heat shock protein 60 correlate with the response of gastric mucosa-associated lymphoid tissue lymphoma to eradication of H. pylori. Helicobacter. 9: 194-200, 2004.
8. Isogai E, Hirata M, Isogai H, Matsuo K, Miura H, and Oguma K. Antimicrobial and lipopolysaccharide-binding activities of C-terminal domain of human CAP18 peptides to genus Leptospira. J. Applied. Res. 4: 180-185, 2004.
9. Shimomura H, Hayashi S, Yokota K, Oguma K, and Hirai Y. Alteration in the composition of cholesteryl glucosides and other lipids in Helicobacter pylori undergoing morphological change from spiral to coccoid form. FEMS Microbiol. Lett. 237: 407-413, 2004.
10. Hasegawa K, Watanabe T, Sato H, Sagane Y, Mutoh S, Suzuki T, Yamano A, Kouguchi H, Takeshi K, Kamaguchi A, Fujinaga Y, Oguma K, and Ohyama T. Characterization of toxin complex produced by a unique strain of Clostridium botulinum serotype D 4947. Protein J. 23: 371-378, 2004.
11. Takenaka R, Yokota K, Ayada K, Mizuno M, Zhao Y, Fujinami Y, Lin SN, Toyokawa T, Okada H, Shiratori Y, and Oguma K. Helicobacter pylori-heat shock protein 60 induces inflammatory responses through the Toll-like receptor-triggered pathway in cultured human gastric epithelial cells. Microbiol. 150: 3913-3922, 2004.
＜2003＞
1. S. Mutoh, H. Kouguchi, Y. Sagane, T. Suzuki, K. Hasegawa, T. Watanabe and T. Ohyama, Complete subunit structure of the Clostridium botulinum type D toxin complex via intermediate assembly with nontoxic components, Biochemistry, 42: 10991-10997, 2003
2. Furuse T, Hasebe S, Ohtsuki H, and Oguma K. Passive length-tensile properties of extraocular muscles under botulinum toxin type C. Jpn. J. Ophthalmol. 47: 145-150, 2003.
3. Tana T, Watarai S, Isogai E, and Oguma K. Induction of intestinal IgA and IgG antibodies preventing adhesion of verotoxin-producing Escherichia coli to Caco-2 cells by oral immunization with liposomes. Lett. Appl. Microbiol. 36:135-139, 2003.
4. Arimitsu H, Inoue K, Sakaguchi Y, Lee J, Fujinaga Y, Watanabe T, Ohyama T, Hirst R, and Oguma K. Purification of fully activated Clostridium botulinum serotype B toxin for treatment of patients with Dystonia. Infect. Immun. 71: 1599-1603, 2003.
5. Woodward LA, Arimitsu H, Hirst R, and Oguma K. Expression of Hc subunits from Clostridium botulinum types C and D and their evaluation as candidate vaccine antigens in mice. Infect. Immun. 71: 2941-2944, 2003.
6. Sagane Y, Hasegawa K, Mutoh S, Kouguchi H, Suzuki T, Sunagawa H, Nakagawa T, Kamaguchi A, Okasaki S, Nakayama K, Watanabe T, Oguma K, and Ohyama T. Molecular characterization of GroES and GroEL homologues from Clostridium botulinum. J. Protein. Chem. 22: 99-108, 2003.
7. Isogai E, Isogai H, Kotake S, Ohno S, Kimura K, and Oguma K. Role of Streptococcus sanguis and traumatic factors in Behcet’s disease. J. Appl. Res. 3:64-75, 2003.
8. Isogai E, Isogai H, Kotake S, Ohno S, Ishimura M, Aoki K, Tojo M, Kaneko F, Yokota K, and Oguma K. Antibody cross reactivity from sera of patients with Behcet’s disease with synthetic peptides that have homologies with proteins from Streptococcus sanguis. J. Appl. Res. 2:185-191, 2003.
9. Isogai E, Hirata M, Isogai H, Matsuo K, Yokota K, Oguma K, Tojyo M, Kaneko F, Kotake S, and Ohno S. Antimicrobial activity of synthetic human CAP18 peptides to Streptococcus sanguis isolated from patients with Behcet’s disease. Adv. Exp. Med. Biol. 528: 195-200, 2003.
10. Nagahara Y, Mizuno M, Maga T, Ishiki K, Okuno T, Yoshida T, Yokota K, Oguma K, Okada H, and Tsuji T. Outcome of patients with inconsistent results from 13C-uera breath test and bacterial culture at the of assessment of Helicobacter pylori eradication therapy in Japan. Hepato-Gastroenterol. 50:1700-1703, 2003.
11. Inoue K, Transue TR, Oguma K, Pederson LC, and Negishi M. Structural analysis by X-ray crystallography and calorimetry of a hemagglutinin component (HA1) of the progenitor toxin from Clostridium botulinum. Microbiol. 149: 3361-3370, 2003.
12. Tanaka S, Mizuno M, Maga T, Yoshinaga F, Tomoda J, Nasu J, Okada H, Yokota K, Oguma K, Shiratori Y, and Tsuji T. H. pylori decreases gastric mucin synthesis via inhibition of galactosyltransferase. Hepato-Gastroentrol. 50: 1739-1742, 2003.
13. Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Inaba T, Yamamoto K, Okada H, Yokota K, Oguma K, and Shiratori Y. Interluekin-1β genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of one-week triple therapy for H. pylori. Am. J. Gastroenterol. 98: 2403-2408, 2003
14. Y. Sagane, K. Hasegawa, S. Mutoh, H. Kouguchi, T. Suzuki, H. Sunagawa, T. Nakagawa, A. Kamaguchi, S. Okasaki, K. Nakayama,T. Watanabe, K. Oguma and T. Ohyama, Molecular characterization of GroES and GroEL homologues from Clostridium botulinum, J. Protein Chem. 22: 99-108, 2003
＜2002＞
1. Mahmut N, Inoue K, Fujinaga Y, Hughes L, Arimitsu H, Sakaguchi Y, Ohtsuka A, Murakami T, Yokota K, and Oguma K. Characterization of monoclonal antibodies against haemagglutinin associated with Clostridium botulinum type C neurotoxin. J. Med. Microbiol. 51: 286-294, 2002.
2. Sagane Y, Watanabe T, Kouguchi H, Sunagawa H, Obata S, Oguma K, and Ohyama T. Spontaneous nicking in the nontoxic-nonhemagglutinin component of the Clostridium botulinum toxin complex. Biochem. Biophysic Res. Communi. 292: 434-440, 2002.
3. Adachi M, Mizuno M, Yokota K, Miyoshi M, Nagahara Y, Maga T, Ishiki K, Inaba T, Okada H, Oguma K, and Tsuji T. Reinfection rate following effective therapy against Helicobaceter pylori infection in Japan. J. Gastroen. Hepatol. 17: 27-31, 2002.
4. Mahmut N, Inoue K, Fujinaga Y, Arimitsu H, Sakaguchi Y, Hughes L, Hirst R, Murphy T, Tsuji T, Watanabe T, Ohyama T, Karasawa T, Nakamura S, Yokota K, and Oguma K. Mucosal immunisation with Clostridium botulinum type C 16S toxoid and its non-toxic component. J. Med. Microbiol. 51: 813-820, 2002.
5. Jin HS, Yoshino T, Jin Z, Oka T, Kobayashi K, Yamasaki R, Liu YX, Yokota K, Oguma K, and Akagi T. Expression of heat shock protein 60 in normal and neoplastic human lymphoid tissues. J. Clin. Exp. Hematopathol. 1: 25-32, 2002.
6. Inaba T, Mizuno M, Kawai K, Yokota K, Oguma K, Miyoshi M, Take S, Okada H, and Tsuji T. Helicobacter pylori infection: cyp2c19 genotype and serum ferritin. J. Gastroen. Hepatol. 17: 748-753, 2002 .
＜2001＞
1. Watarai S, Tana T, Inoue K, Kushi Y, Isogai E, Yokota K, Naka K, Oguma K, and Kodama H. Inhibition of Vero cell cytotoxic activity in Escherichia coli O157: H7 lysates by globotriaosylceramide, Gb3, from bovine milk. Biosci. Biotechnol. Biochem. 65: 414-419, 2001.
2. Naka K, Watarai S, Tana, Inoue K, Kodama Y, Oguma K, Yasuda T, and Kodama H. Adsorption effect of activated charcoal on enterohemorrhagic Escherichia coli. J. Vet. Med. Sci. 63: 281-285, 2001.
3. Watarai S, Yokota K, Tana T, Kishimoto T, Kanadani K, Taketa K, and Oguma K. Relationship between susceptibility to hemolytic-uremic syndrome and levels of globotriaosylceramide in human sera. J. Clin. Microbiol. 39: 798-800, 2001.
4. Isogai E, Isogai H, Hirose K, Hayashi S, and Oguma K. In vivo synergy between green tea extract and levofloxacin against enterohemorrhagic Escherichia coli O157 infection. Curr. Microbiol. 42: 248-251, 2001.
5. Miyoshi M, Mizuno M, Ishiki K, Nagahara Y, Maga T, Torigoe T, Nasu J, Okada H, Yokota K, Oguma K, and Tuji T. A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism. J. Gastroenterol. Hepatol. 16: 723-728, 2001.
6. Inoue K, Fujinaga Y, Honke K, Arimitsu H, Mahmut N, Sakaguchi Y, Ohyama, Watanabe T, Inoue K, and Oguma K. Clostridium botulinum type A HA positive progenitor toxin (HA+-PTX) binds to oligosaccharides containing Galβ1-4GlcNAc through one subcomponent of HA (HA1). Microbiol. 147: 811-819, 2001.
7. Jiang HX, Pu H, Huh NH, Yokota K, Oguma K, and Namba M. Helicobacter pylori induces pepsinogen secretion by rat gastric cells in culture via a cAMP signal pathway. Int. J. Molecul. Med. 7: 625-629, 2001.
8. Isogai E, Isogai H, Hirose K, Kubota T, Kimura K, Fujii N, Hayashi S, Takeshi K, and Oguma K. Therapeutic effect of anti-TNF-αand levofloxacin (LVFX) in a mouse model of enterohemorrhagic Escherichia coli O157 infection. Comp. Immunol. Microbiol. Inf. Dis. 24: 217-231, 2001.
9. Sagane Y, Kouguchi H, Watanabe T, Sunagawa H, Inoue K, Fujinaga Y, Oguma K, and Ohyama T. Role of C-terminal region of HA-33 component of botulinum toxin in hemagglutination. Biochem. Bioph. Res. Communi. 288: 650-657, 2001.
10. Ishii E, Yokota K, Sugiyama T, Fujinaga Y, Ayada K, Hokari I, Hayashi S, Hirai Y, Asaka M, and Oguma K. Immunoglobulin G1 antibody response to Helicobacter pylori heat shock protein 60 is closely associated with low-grade gastric mucosa-associated lymphoid tissue lymphoma. Clin. Diagn. Lab. Immunol. 8: 1056-1059, 2001.
＜2000＞
1. Fujinaga Y, Inoue K, Nomura T, Sasaki J, Marvaud J. C., Popoff M. R., Kozaki S, and Oguma K. Identification and characterization of functional subunits of Clostridium botulinum type A progenitor toxin involved in binding to intestinal microvilli and erythrocytes. FEBS Lett. 467: 179-183, 2000.
2. Hayashi S, Sugiyama T, Yokota K, Isogai H, Isogai E, Shimomura H, Oguma K, Asaka M, and Hirai Y. Combined effect of rebamipide and ecabet sodium on Helicobacter pylori adhesion to gastric epithelial cells. Microbiol. Immunol. 44: 557-562, 2000.
3. Yunoki, N, Yokota k., Mizuno M, Kawahara Y, Adachi M, Okada H, Hayashi S, Hirai Y, Oguma K, and Tsuji T. Antibody to heat shock protein can be used for early serological monitoring of Helicobacter pylori eradication treatment. Clin. Diagn. Lab. Immunol. 7: 574-577, 2000.
4. Hayashi S, Hirai Y, Isogai H, Isogai E, Yokota K, and Oguma K. Treatment of Helicobacter pylori infection. Res Adv in Antimicrob. Agents & Chemother. 1: 7-12, 2000.
5. Wang X, Maegawa T, Karasawa T, Kozaki S, Tsukamoto K, Gyobu Y, Yamakawa K, Oguma K, Sakaguchi Y, and Nakamura S. Genetic analysis of type E botulinum toxin - producing Clostridium butyricum strains. Appl. Environ. Microbiol. 66: 4992-4997, 2000.
6. Sagane Y, Watanabe T, Kouguchi H, Sunagawa H, Inoue K, Fujinaga Y, Oguma K, and Ohyama T. Characterization of nicking of the nontoxic-nonhemagglutinin components of Clostridium botulinum types C and D progenitor toxin. J. Protein Chem. 19: 575-581, 2000.
7. Murphy T, Lawson A, Nalewajko C, Murkin H, Ross L, Oguma K, and Mclntyre T. Algal toxins-initiators of avian botulism? Environ. Toxicol. 15: 558-567, 2000.
8. Watarai S, Tana T, Inoue K, Oguma K, Naka K, and Kodama H. Inhibitory sffect of intestinal anti-globotriaosylceramide IgA antibody on verotoxin-induced cytotoxicity. Lett. Appl. Microbiol. 31: 449-453, 2000. .
1. Toyokawa T, Yokota K, Mizuno M, Fujinami Y, Takenaka R, Okada H, Hayashi S, Hirai Y, Oguma K, and Shiratori S. Characterization of elongated Helicobacter pylori isolated from a patient with gastric-mucosa-associated lymphoid-tissue lymphoma. J. Med. Microbiol. 53: 1-6, 2004.
2. Yamasaki R, Yokota K, Okada H, Hayashi S, Mizuno M, Yoshino T, Hirai Y, Saitou D, Akagi T, and Oguma K. Immune response in Helicobacter pylori-induced low-grade gastric-mucosa-associated lymphoid tissue (MALT) lymphoma. J Med Microbiol. 53:21-29, 2004.
3. Fujinaga Y, Inoue K, Watarai S, Sakaguchi Y, Arimitsu H, Lee J, Jin Y, Matsumura T, Kabumoto Y, Watanabe T, Ohyama T, Nishikawa A, and Oguma K. Molecular characterization of binding subcomponents of Clostridium botulinum type C progenitor toxin for intestinal epithelial cells and erythrocytes. Microbiol. 150: 1529-1538, 2004.
4. Arimitsu H, Lee J, Sakaguchi Y, Hayakawa Y, Hayashi M, Nakaura M, Takai H, Lin SN, Mukamoto M, Murphy T, and Oguma K. Vaccination with recombinant whole heavy chain fragments of Clostridium botulinum type C and D neurotoxins. Clin Diagn Lab Immunol. 11: 496-502, 2004.
5. Nishikawa A, Uotsu N, Miura Y, Arimitsu H, Lee J, Fujinaga Y, Nakada H, Ohyama T, Sakano Y, and Oguma K. The receptor and transporter for internalization of Clostridium botulinum type C progenitor toxin into HT-29 cells. Biochem. Biophysic Res. Communi. 319: 327-333, 2004.
6. Ishiki K, Mizuno M, Take S, Nagahara Y, Yoshida T, Yamamoto K, Okada H, Yokota K, Oguma K, and Shiratori Y. Helicobacter pylori eradication improves pre-existing reflux esophagitis in patients with duodenal disease. Clin. Gastroenterol. Hepatol. 2: 474-479, 2004.
7. Takenaka R, Yokota K, Mizuno M, Okada H, Toyokawa T, Yamasaki R, Yoshino T, Sugiyama T, Asaka M, Shiratori Y, and Oguma K. Serum antibodies to Helicobacter pylori and its heat shock protein 60 correlate with the response of gastric mucosa-associated lymphoid tissue lymphoma to eradication of H. pylori. Helicobacter. 9: 194-200, 2004.
8. Isogai E, Hirata M, Isogai H, Matsuo K, Miura H, and Oguma K. Antimicrobial and lipopolysaccharide-binding activities of C-terminal domain of human CAP18 peptides to genus Leptospira. J. Applied. Res. 4: 180-185, 2004.
9. Shimomura H, Hayashi S, Yokota K, Oguma K, and Hirai Y. Alteration in the composition of cholesteryl glucosides and other lipids in Helicobacter pylori undergoing morphological change from spiral to coccoid form. FEMS Microbiol. Lett. 237: 407-413, 2004.
10. Hasegawa K, Watanabe T, Sato H, Sagane Y, Mutoh S, Suzuki T, Yamano A, Kouguchi H, Takeshi K, Kamaguchi A, Fujinaga Y, Oguma K, and Ohyama T. Characterization of toxin complex produced by a unique strain of Clostridium botulinum serotype D 4947. Protein J. 23: 371-378, 2004.
11. Takenaka R, Yokota K, Ayada K, Mizuno M, Zhao Y, Fujinami Y, Lin SN, Toyokawa T, Okada H, Shiratori Y, and Oguma K. Helicobacter pylori-heat shock protein 60 induces inflammatory responses through the Toll-like receptor-triggered pathway in cultured human gastric epithelial cells. Microbiol. 150: 3913-3922, 2004.
＜2003＞
1. S. Mutoh, H. Kouguchi, Y. Sagane, T. Suzuki, K. Hasegawa, T. Watanabe and T. Ohyama, Complete subunit structure of the Clostridium botulinum type D toxin complex via intermediate assembly with nontoxic components, Biochemistry, 42: 10991-10997, 2003
2. Furuse T, Hasebe S, Ohtsuki H, and Oguma K. Passive length-tensile properties of extraocular muscles under botulinum toxin type C. Jpn. J. Ophthalmol. 47: 145-150, 2003.
3. Tana T, Watarai S, Isogai E, and Oguma K. Induction of intestinal IgA and IgG antibodies preventing adhesion of verotoxin-producing Escherichia coli to Caco-2 cells by oral immunization with liposomes. Lett. Appl. Microbiol. 36:135-139, 2003.
4. Arimitsu H, Inoue K, Sakaguchi Y, Lee J, Fujinaga Y, Watanabe T, Ohyama T, Hirst R, and Oguma K. Purification of fully activated Clostridium botulinum serotype B toxin for treatment of patients with Dystonia. Infect. Immun. 71: 1599-1603, 2003.
5. Woodward LA, Arimitsu H, Hirst R, and Oguma K. Expression of Hc subunits from Clostridium botulinum types C and D and their evaluation as candidate vaccine antigens in mice. Infect. Immun. 71: 2941-2944, 2003.
6. Sagane Y, Hasegawa K, Mutoh S, Kouguchi H, Suzuki T, Sunagawa H, Nakagawa T, Kamaguchi A, Okasaki S, Nakayama K, Watanabe T, Oguma K, and Ohyama T. Molecular characterization of GroES and GroEL homologues from Clostridium botulinum. J. Protein. Chem. 22: 99-108, 2003.
7. Isogai E, Isogai H, Kotake S, Ohno S, Kimura K, and Oguma K. Role of Streptococcus sanguis and traumatic factors in Behcet’s disease. J. Appl. Res. 3:64-75, 2003.
8. Isogai E, Isogai H, Kotake S, Ohno S, Ishimura M, Aoki K, Tojo M, Kaneko F, Yokota K, and Oguma K. Antibody cross reactivity from sera of patients with Behcet’s disease with synthetic peptides that have homologies with proteins from Streptococcus sanguis. J. Appl. Res. 2:185-191, 2003.
9. Isogai E, Hirata M, Isogai H, Matsuo K, Yokota K, Oguma K, Tojyo M, Kaneko F, Kotake S, and Ohno S. Antimicrobial activity of synthetic human CAP18 peptides to Streptococcus sanguis isolated from patients with Behcet’s disease. Adv. Exp. Med. Biol. 528: 195-200, 2003.
10. Nagahara Y, Mizuno M, Maga T, Ishiki K, Okuno T, Yoshida T, Yokota K, Oguma K, Okada H, and Tsuji T. Outcome of patients with inconsistent results from 13C-uera breath test and bacterial culture at the of assessment of Helicobacter pylori eradication therapy in Japan. Hepato-Gastroenterol. 50:1700-1703, 2003.
11. Inoue K, Transue TR, Oguma K, Pederson LC, and Negishi M. Structural analysis by X-ray crystallography and calorimetry of a hemagglutinin component (HA1) of the progenitor toxin from Clostridium botulinum. Microbiol. 149: 3361-3370, 2003.
12. Tanaka S, Mizuno M, Maga T, Yoshinaga F, Tomoda J, Nasu J, Okada H, Yokota K, Oguma K, Shiratori Y, and Tsuji T. H. pylori decreases gastric mucin synthesis via inhibition of galactosyltransferase. Hepato-Gastroentrol. 50: 1739-1742, 2003.
13. Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Inaba T, Yamamoto K, Okada H, Yokota K, Oguma K, and Shiratori Y. Interluekin-1β genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of one-week triple therapy for H. pylori. Am. J. Gastroenterol. 98: 2403-2408, 2003
14. Y. Sagane, K. Hasegawa, S. Mutoh, H. Kouguchi, T. Suzuki, H. Sunagawa, T. Nakagawa, A. Kamaguchi, S. Okasaki, K. Nakayama,T. Watanabe, K. Oguma and T. Ohyama, Molecular characterization of GroES and GroEL homologues from Clostridium botulinum, J. Protein Chem. 22: 99-108, 2003
＜2002＞
1. Mahmut N, Inoue K, Fujinaga Y, Hughes L, Arimitsu H, Sakaguchi Y, Ohtsuka A, Murakami T, Yokota K, and Oguma K. Characterization of monoclonal antibodies against haemagglutinin associated with Clostridium botulinum type C neurotoxin. J. Med. Microbiol. 51: 286-294, 2002.
2. Sagane Y, Watanabe T, Kouguchi H, Sunagawa H, Obata S, Oguma K, and Ohyama T. Spontaneous nicking in the nontoxic-nonhemagglutinin component of the Clostridium botulinum toxin complex. Biochem. Biophysic Res. Communi. 292: 434-440, 2002.
3. Adachi M, Mizuno M, Yokota K, Miyoshi M, Nagahara Y, Maga T, Ishiki K, Inaba T, Okada H, Oguma K, and Tsuji T. Reinfection rate following effective therapy against Helicobaceter pylori infection in Japan. J. Gastroen. Hepatol. 17: 27-31, 2002.
4. Mahmut N, Inoue K, Fujinaga Y, Arimitsu H, Sakaguchi Y, Hughes L, Hirst R, Murphy T, Tsuji T, Watanabe T, Ohyama T, Karasawa T, Nakamura S, Yokota K, and Oguma K. Mucosal immunisation with Clostridium botulinum type C 16S toxoid and its non-toxic component. J. Med. Microbiol. 51: 813-820, 2002.
5. Jin HS, Yoshino T, Jin Z, Oka T, Kobayashi K, Yamasaki R, Liu YX, Yokota K, Oguma K, and Akagi T. Expression of heat shock protein 60 in normal and neoplastic human lymphoid tissues. J. Clin. Exp. Hematopathol. 1: 25-32, 2002.
6. Inaba T, Mizuno M, Kawai K, Yokota K, Oguma K, Miyoshi M, Take S, Okada H, and Tsuji T. Helicobacter pylori infection: cyp2c19 genotype and serum ferritin. J. Gastroen. Hepatol. 17: 748-753, 2002 .
＜2001＞
1. Watarai S, Tana T, Inoue K, Kushi Y, Isogai E, Yokota K, Naka K, Oguma K, and Kodama H. Inhibition of Vero cell cytotoxic activity in Escherichia coli O157: H7 lysates by globotriaosylceramide, Gb3, from bovine milk. Biosci. Biotechnol. Biochem. 65: 414-419, 2001.
2. Naka K, Watarai S, Tana, Inoue K, Kodama Y, Oguma K, Yasuda T, and Kodama H. Adsorption effect of activated charcoal on enterohemorrhagic Escherichia coli. J. Vet. Med. Sci. 63: 281-285, 2001.
3. Watarai S, Yokota K, Tana T, Kishimoto T, Kanadani K, Taketa K, and Oguma K. Relationship between susceptibility to hemolytic-uremic syndrome and levels of globotriaosylceramide in human sera. J. Clin. Microbiol. 39: 798-800, 2001.
4. Isogai E, Isogai H, Hirose K, Hayashi S, and Oguma K. In vivo synergy between green tea extract and levofloxacin against enterohemorrhagic Escherichia coli O157 infection. Curr. Microbiol. 42: 248-251, 2001.
5. Miyoshi M, Mizuno M, Ishiki K, Nagahara Y, Maga T, Torigoe T, Nasu J, Okada H, Yokota K, Oguma K, and Tuji T. A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism. J. Gastroenterol. Hepatol. 16: 723-728, 2001.
6. Inoue K, Fujinaga Y, Honke K, Arimitsu H, Mahmut N, Sakaguchi Y, Ohyama, Watanabe T, Inoue K, and Oguma K. Clostridium botulinum type A HA positive progenitor toxin (HA+-PTX) binds to oligosaccharides containing Galβ1-4GlcNAc through one subcomponent of HA (HA1). Microbiol. 147: 811-819, 2001.
7. Jiang HX, Pu H, Huh NH, Yokota K, Oguma K, and Namba M. Helicobacter pylori induces pepsinogen secretion by rat gastric cells in culture via a cAMP signal pathway. Int. J. Molecul. Med. 7: 625-629, 2001.
8. Isogai E, Isogai H, Hirose K, Kubota T, Kimura K, Fujii N, Hayashi S, Takeshi K, and Oguma K. Therapeutic effect of anti-TNF-αand levofloxacin (LVFX) in a mouse model of enterohemorrhagic Escherichia coli O157 infection. Comp. Immunol. Microbiol. Inf. Dis. 24: 217-231, 2001.
9. Sagane Y, Kouguchi H, Watanabe T, Sunagawa H, Inoue K, Fujinaga Y, Oguma K, and Ohyama T. Role of C-terminal region of HA-33 component of botulinum toxin in hemagglutination. Biochem. Bioph. Res. Communi. 288: 650-657, 2001.
10. Ishii E, Yokota K, Sugiyama T, Fujinaga Y, Ayada K, Hokari I, Hayashi S, Hirai Y, Asaka M, and Oguma K. Immunoglobulin G1 antibody response to Helicobacter pylori heat shock protein 60 is closely associated with low-grade gastric mucosa-associated lymphoid tissue lymphoma. Clin. Diagn. Lab. Immunol. 8: 1056-1059, 2001.
＜2000＞
1. Fujinaga Y, Inoue K, Nomura T, Sasaki J, Marvaud J. C., Popoff M. R., Kozaki S, and Oguma K. Identification and characterization of functional subunits of Clostridium botulinum type A progenitor toxin involved in binding to intestinal microvilli and erythrocytes. FEBS Lett. 467: 179-183, 2000.
2. Hayashi S, Sugiyama T, Yokota K, Isogai H, Isogai E, Shimomura H, Oguma K, Asaka M, and Hirai Y. Combined effect of rebamipide and ecabet sodium on Helicobacter pylori adhesion to gastric epithelial cells. Microbiol. Immunol. 44: 557-562, 2000.
3. Yunoki, N, Yokota k., Mizuno M, Kawahara Y, Adachi M, Okada H, Hayashi S, Hirai Y, Oguma K, and Tsuji T. Antibody to heat shock protein can be used for early serological monitoring of Helicobacter pylori eradication treatment. Clin. Diagn. Lab. Immunol. 7: 574-577, 2000.
4. Hayashi S, Hirai Y, Isogai H, Isogai E, Yokota K, and Oguma K. Treatment of Helicobacter pylori infection. Res Adv in Antimicrob. Agents & Chemother. 1: 7-12, 2000.
5. Wang X, Maegawa T, Karasawa T, Kozaki S, Tsukamoto K, Gyobu Y, Yamakawa K, Oguma K, Sakaguchi Y, and Nakamura S. Genetic analysis of type E botulinum toxin - producing Clostridium butyricum strains. Appl. Environ. Microbiol. 66: 4992-4997, 2000.
6. Sagane Y, Watanabe T, Kouguchi H, Sunagawa H, Inoue K, Fujinaga Y, Oguma K, and Ohyama T. Characterization of nicking of the nontoxic-nonhemagglutinin components of Clostridium botulinum types C and D progenitor toxin. J. Protein Chem. 19: 575-581, 2000.
7. Murphy T, Lawson A, Nalewajko C, Murkin H, Ross L, Oguma K, and Mclntyre T. Algal toxins-initiators of avian botulism? Environ. Toxicol. 15: 558-567, 2000.
8. Watarai S, Tana T, Inoue K, Oguma K, Naka K, and Kodama H. Inhibitory sffect of intestinal anti-globotriaosylceramide IgA antibody on verotoxin-induced cytotoxicity. Lett. Appl. Microbiol. 31: 449-453, 2000. .
2000〜2004年 原著論文（計49報）